Results 41 to 50 of about 313,411 (354)

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study [PDF]

, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulating levels are significantly associated with an increased risk of cardiovascular events.
Borghi, Claudio, Botta, Margherita, Cicero, Arrigo F. G., D'Addato, Sergio, Ferri, Nicola, Fogacci, Federica, Giovannini, Marina, Magni, Paolo, Marchiano, Silvia, Rosticci, Martina, Ruscica, Massimiliano   +10 more
core   +2 more sources

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts

Frontiers in Endocrinology, 2021
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been implicated in the pathogenesis of inflammatory diseases. We sought to investigate the role of PCSK9 in the pathogenesis of Graves’ orbitopathy (GO) and whether it may be a ...
Ga‐Eun Lee, Jinjoo Kim, J. Lee, JaeSang Ko, E. J. Lee, J. Yoon   +5 more
semanticscholar   +1 more source

A novel familial mutation in the PCSK1 gene that alters the oxyanion hole residue of proprotein convertase 1/3 and impairs its enzymatic activity. [PDF]

, 2014
Four siblings presented with congenital diarrhea and various endocrinopathies. Exome sequencing and homozygosity mapping identified five regions, comprising 337 protein-coding genes that were shared by three affected siblings. Exome sequencing identified
Abbasi, Montaser, Bar-Oz, Benjamin, Berger, Itai, Blanco, Elias, Elpeleg, Orly, Lindberg, Iris, Martín, Martin G, Pappo, Orit, Shteyer, Eyal, Wilschanski, Michael, Yourshaw, Michael, Zangen, David   +11 more
core   +2 more sources

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

Медицинский совет, 2021
Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva, M. L. Maximov, N. M. Kiseleva   +2 more
doaj   +1 more source

A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

CPT: Pharmacometrics &Systems Pharmacology, Volume 11, Issue 12, Page 1569-1577, December 2022., 2022
Abstract Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines ...
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson‐Löfmark, Rikard Isaksson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić   +10 more
wiley   +1 more source

PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. [PDF]

, 2016
Prohormone convertase 1/3, encoded by the PCSK1 gene, is a serine endoprotease that is involved in the processing of a variety of proneuropeptides and prohormones. Humans who are homozygous or compound heterozygous for loss-of-function mutations in PCSK1

core   +2 more sources

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults

Metabolites, 2022
Background: High levels of non-HDL cholesterol (non-HDL-C), triglycerides (TG), lipoprotein (a) (Lp(a)), and Proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as low levels of HDL-C are strongly associated with cardiovascular disease (CVD ...
Marie-Hélène Gannagé-Yared, Elie Naous, Anis Al Achkar, Wadih Issa, Ghassan Sleilaty, Vanda Barakett-Hamade, Marianne Abifadel   +6 more
doaj   +1 more source

Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line [PDF]

, 2015
The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor (TNF-\u3b1).
Corsini, Alberto, Cristofani, Riccardo, Ferri, Nicola, Liu, Jingwen, Macchi, Chiara, Magni, Paolo, Ricci, Chiara, Ruscica, Massimiliano   +7 more
core   +2 more sources

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and ...
R. Giugliano, T. Pedersen, J. Saver, P. Sever, A. Keech, E. Bohula, S. Murphy, S. Wasserman, Narimon Honarpour, Hong Wang, Armando Lira Pineda, M. Sabatine   +11 more
semanticscholar   +1 more source

Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States

Circulation. Cardiovascular Quality and Outcomes, 2021
Supplemental Digital Content is available in the text. Background: Marketing payments from the pharmaceutical industry to physicians have come under scrutiny due to their potential to influence clinical decision-making.
Kosuke Inoue, J. Figueroa, C. DeJong, Y. Tsugawa, E. J. Orav, Changyu Shen, Dhruv S. Kazi   +6 more
semanticscholar   +1 more source